Pharmacogenomic insights into treatment and management of statin-induced myopathy

被引：0
作者：
Bas JM Peters
Olaf H Klungel
Frank L Visseren
Anthonius de Boer
Anke-Hilse Maitland-van der Zee
机构：
[1] University of Utrecht,Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS)
[2] University Medical Centre Utrecht,Department of Vascular Medicine
来源：
Genome Medicine | / 1卷
关键词：
Simvastatin; Atorvastatin; Myopathy; Pravastatin; Statin Therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Although statins are generally well tolerated, the most common adverse drug reaction from statin therapy is myopathy. This article reviews the current pharmacogenomic knowledge of statin-induced myopathy. Furthermore, we will discuss the importance of recent pharmacogenetic advances for the treatment and management of statin-induced myopathy. Variation in the SLCO1B1 gene is associated with increased incidence of statin-induced myopathy, particularly with simvastatin and less so with other statins. If different pharmacokinetic enzymes and transporters are responsible for susceptibility to myopathy, this may explain differences in the occurrence of statin-induced myopathy in individual patients. Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin for the lowest chance of developing myopathy.
引用
收藏
相关论文
共 140 条
[1]  
Pasternak RC(2002)ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Stroke 33 2337-2341
[2]  
Smith SC(2006)Statin safety: a systematic review Am J Cardiol 97 52C-60C
[3]  
Bairey-Merz CN(2004)Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs JAMA 292 2585-2590
[4]  
Grundy SM(2005)Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 403-414
[5]  
Cleeman JI(2007)Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients Clin Ther 29 1761-1770
[6]  
Lenfant C(2009)Narrative review: statin-related myopathy Ann Intern Med 150 858-868
[7]  
Law M(2003)Influence of Clin Pharmacol Ther 74 186-194
[8]  
Rudnicka AR(2004) polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers J Hum Genet 49 582-585
[9]  
Graham DJ(2005)A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin J Clin Pharm Ther 30 189-192
[10]  
Staffa JA(2005)Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis Pharmacogenet Genomics 15 415-421
12345678910